What makes ICX-TRC a failure, in my view, is that it has not lived up to Intercytex’s rhetoric. Using the internet archive “wayback” machine you can see old pages of ICX-TRC. Here’s a brief tour:
Nov 23, 2005:
“The first part of a Phase I clinical trial (safety) has been completed in seven volunteers at a single UK transplant centre. No safety issues have arisen and five out of the seven patients have shown increased hair numbers. The second part of this Phase I safety study is actively recruiting volunteers, this will be followed by a multi-centre Phase II clinical efficacy trial on patients with male pattern baldness. The Phase II trial is planned for the first half of 2006 and will be performed in both the UK and North America. A Phase III trial for both male pattern baldness and female diffuse alopecia will be conducted in 2007.”
Failures: No multi-center (just uni-center) phase II in first half of 2006; no phase II trials in North America; no Phase III in 2007; definitely no phase III for female diffuse alopecia.
Nov 18, 2006:
“Recruitment for Phase II clinical efficacy trial on patients with male pattern baldness has commenced in the UK with an initial cohort of up to 20 subjects which will be followed by variations in delivery technique in further similar sized cohorts. The trial is designed to demonstrate efficacy of ICX-TRC, the dosage regime and the delivery device. Preliminary data from this trial are expected during the first half of 2007.”
Failures: nowhere near 20 people in each cohort (though the text above does say “up to 20” if you want to be a hairsplitter); data not available until second half of 2007, not first half.
So let’s stop pretending this is good news. It ain’t. It’s laughably bad!